The Carlyle Group to acquire a 5% stake in Shenzhen Salubris Pharmaceuticals for $260m.

The Carlyle Group agreed to acquire a 5% stake in Shenzhen Salubris Pharmaceuticals, a Chinese pharmaceutical company, for $260m. Carlyle stepped up health-care investments in China, buying stakes in third party independent clinical laboratory Adicon and global peptide API’s manufacturer Ambio in 2018. Globally, Carlyle has invested more than $13.4bn of equity in more than 80 deals in the global health care sector as of June 2020.